MAPT and Alzheimer disease: We also found that change in IIV over time was associated with reduced CBF in AD vulnerable regions in p-tau/Aβ+ individuals, suggesting that evolving pathology and increasing IIV may be occurring within this relatively short follow-up period of 1 year among individuals presumed to be on the AD continuum (i.e., p-tau/Aβ+).